A phase I study of a DNA vaccine targeting prostatic acid phosphatase in patients with stage D0 prostate cancer

Clinical Genitourinary Cancer

Volumn 4, Issue 3, 2005, Pages 215-218

  Zlotocha, Sarah ^a   Staab, Mary Jane ^a   Horvath, Dorothy ^a   Straus, Jane ^a   Dobratz, Jeanne ^a   Oliver, Katherine ^a   Wasielewski, Stephine ^a   Alberti, Dona ^a   Liu, Glenn ^a   Wilding, George ^a   Eickhoff, Jens ^a,b   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Clinical trials; Prostate specific antigen; Radiation therapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROSTATE SPECIFIC ANTIGEN; ALPHA INTERFERON; IMMUNOLOGICAL ADJUVANT; PROTEIN TYROSINE PHOSPHATASE;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; OPEN STUDY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PROSTATE CANCER; REVIEW; TREATMENT PLANNING; ADENOCARCINOMA; ARTICLE; BIOSYNTHESIS; CANCER STAGING; DRUG ANTAGONISM; IMMUNOLOGY; MALE; PATHOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; CD8-POSITIVE T-LYMPHOCYTES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-ALPHA; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; TREATMENT OUTCOME; VACCINES, DNA;

EID: 33644937673     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2005.n.036     Document Type: Article

References (16)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [published erratum in CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
2. Oefelein MG, Smith ND, Grayhack JT, et al. Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol 1997; 158:1460-1465.
3. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281:1591-1597.
4. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294:433-439.
5. McNeel DG, Malkovsky M. Immune-based therapies for prostate cancer. Immunol Lett 2005; 96:3-9.
6. McNeel DG. Prostate cancer antigens and vaccines, preclinical developments. Cancer Chemother Biol Response Modif 2005; 22:247-261.
7. Soanes WA, Ablin RJ, Gonder MJ. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol 1970; 104:154-159.
8. Ablin RJ, Soanes WA, Gonder MJ. Elution of in vivo bound antiprostatic epithelial antibodies following multiple cryotherapy of carcinoma of prostate. Urology 1973; 2:276-279.
9. Gutman AB, Gutman EB. An acid phosphatase in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938; 17:473-479.
10. Terracio L, Rule A, Salvato J, et al. Immunofluorescent localization of an androgen-dependent isoenzyme of prostatic acid phosphatase in rat ventral prostate. Anat Rec 1985; 213:131-139.
11. Fong L, Ruegg CL, Brockstedt D, et al. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization; implications for immunotherapy of prostate cancer. J Immunol 1997; 159:3113-3117.
12. Johnson LE, Frye TP, Arnot AR, et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2005.
13. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175-2182.
14. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894-3903.
15. Fong L, Benike C, Brockstedt D, et al. Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase (PAP) administered via different routes induces cellular immune responses in prostate cancer patients. Proc Amer Assn Canc Res 1999; 40:85.
16. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91:688-694.